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Conclusions and Future Implications
Table 1. Timing of Various Health System Steps
 
BP Identification to physician/
Midwife Notification
(minutes)
Notification to Medication Order
(minutes)
Order to Medication 
Administration 
(minutes)
BP Identification to Medication 
Administration Total
(minutes)




Mean 12.1 15.8 13.1 41.0 31.3
Median 7 10 11 36 27
Range 0-60 0-69 0-43 9-87 7-75
 
Methodology
© 2017 Lehigh Valley Health Network
•  Preeclampsia occurs in 2-8% of pregnant 
women and can occur with and without severe 
features.1 
•  One feature that defines preeclampsia with 
severe features is elevations of SBP >160mmHg 
and/or DBP >110mmHg, which can lead to 
serious adverse maternal and fetal outcomes 
including death.2,3
•  In order to prevent adverse events, the 
California Maternal Quality Care Collaborative 
(CMQCC) recommends that patients should be 
evaluated promptly and receive antihypertensive 
medications within 60 minutes, and ideally 
within 30 minutes.4
•  Frequent reassessment and administration of 
escalating doses of antihypertensive medications 
should occur to decrease the risk of adverse 
events.4
•  LVHN Department of Ob/Gyn established 
a clinical practice guideline to establish a 
standardized way to identify and manage 
severe-range hypertension in the peripartum 
period (Figure 1).
•  76 patients were identified.  Of these, 36 patients remained following exclusion.
•  The mean, median, and range of time elapsed between various steps from blood pressure identification to 
medication administration are reported in Table 1.
•  The number of patients who were treated appropriately as defined by the LVHN clinical practice guideline are 
reported in Figure 2.
•  1 patient received PO nifedipine rather than the recommended IV labetalol or hydralazine.
•  On average, healthcare providers met the recommended blood pressure confirmation-to-medication 
administration time of within 60 and 30 minutes.
•  On average, healthcare providers did not meet the recommended time for blood pressure rechecks.
•  About 1 out of 4 patients received an incorrect second antihypertensive when found to have persistently 
severe-range blood pressure upon reassessment.
•  These findings allow for a number of health system improvements to be made to increase the quality of 
patient care at LVHN.  These include but are not limited to: physician/midwife notification following first 
severe-range blood pressure, Epic changes, healthcare professional education, and posting the clinical 
pathway in an easily-accessible location on the labor & delivery floor for reference.
This quality improvement project aims to identify 
whether healthcare providers at LVHN provide 
timely and appropriate management of severe-
range hypertension on the labor and delivery floor, 
based on the established clinical practice guideline.
•  Following IRB exemption, a retrospective chart 
review was performed to identify patients 
with preeclampsia with severe features in the 
peripartum period at LVHN during the months of 
December 2015 to May 2016.
•  Patients without SBP >160mmHg or DBP 
>110mmHg and those who did not receive 
antihypertensive medication were excluded.
•  Management of these patients as compared 
to the clinical practice guideline at LVHN was 
analyzed.
•  Descriptive statistics were used to assess the 
distributions of the examined variables. 
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RN reports to bedside to assess
Patient for symptoms and to
Repeat manual BP
RN calls x5368 with SBAR to
Chief resident
RN obtains VI access if not
Already in place
Chief resident or designee




Chest pain, SOB, etc)
• MBU – prepare for transfer to PNU, L&D 
charge nurse is notified
• Consider magnesium sulfate
• Consider imaging as appropriate
Patient may initially
Remain in current unit
For treatment
Labetalol 20 mg IV
• Repeat BP in 20 minutes
• Resident to notify attending physician
• TP brings portable cardiac monitor to room
Labetalol 40 mg IV
• Requires cardiac monitoring OR must be 
given by MD/DO
• Resident to notify attending physician
• MBU-Prepare for transfer to PNU if not 
already done; Notify L&D charge nurse
• Repeat BP in 10 minutes
Labetalol 80 mg IV
• Repeat BP in 10 minutes
• Attending should be notified to report to 
bedside
• Notify MFM
Hydralazine 5-10 mg IV
• Repeat BP in 20 minutes
• Resident to notify attending physician
Hydralazine 10 mg IV
• MBU-Prepare for transfer to PNU if not 
already done; Notify L%L charge nurse
• Resident to notify attending physician
• Repeat BP in 20 minutes
Labetalol 20 mg IV
• Repeat BP in 20 minutes
• Attending should be notified to report to 
bedside
• Notify MFM
SBP>160 OR DBP >110
Continue on algorithm
SBP<160 AND DBP <110
• Repeat BP every 30 
minutes x2, then every 
one hour x3 then every 4 
hours
• Consider the need for oral 
antihypertensive 
medication or dose 
adjustment
NO YES
Hydralazine 10 mg IV
• Repeat BP in 20 minutes
• Consider notification of cardiologist, 
anesthesiologist, or critical care
Labetalol 40 mg IV
• Repeat BP in 10 minutes
• Consider notification of cardiologist, 



















Medication Within 30 Minutes
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Figure 1. Hypertensive Emergency Pathway for Peripartum Patients
Figure 2. 
